CA2720616C - Treatment of tumours - Google Patents

Treatment of tumours Download PDF

Info

Publication number
CA2720616C
CA2720616C CA2720616A CA2720616A CA2720616C CA 2720616 C CA2720616 C CA 2720616C CA 2720616 A CA2720616 A CA 2720616A CA 2720616 A CA2720616 A CA 2720616A CA 2720616 C CA2720616 C CA 2720616C
Authority
CA
Canada
Prior art keywords
ace2
tumour
use according
cancer
ang
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2720616A
Other languages
English (en)
French (fr)
Other versions
CA2720616A1 (en
Inventor
Evelyne Janzek-Hawlat
Hans Loibner
Manfred Schuster
Bernhard Peball
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeiron Biologics GmbH
Original Assignee
Apeiron Biologics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics GmbH filed Critical Apeiron Biologics GmbH
Publication of CA2720616A1 publication Critical patent/CA2720616A1/en
Application granted granted Critical
Publication of CA2720616C publication Critical patent/CA2720616C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2720616A 2008-04-09 2009-04-07 Treatment of tumours Active CA2720616C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA566/2008 2008-04-09
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen

Publications (2)

Publication Number Publication Date
CA2720616A1 CA2720616A1 (en) 2009-10-15
CA2720616C true CA2720616C (en) 2016-08-09

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720616A Active CA2720616C (en) 2008-04-09 2009-04-07 Treatment of tumours

Country Status (12)

Country Link
US (1) US8946162B2 (https=)
EP (2) EP2644203A1 (https=)
JP (1) JP5650639B2 (https=)
AT (1) AT506632A1 (https=)
AU (1) AU2009235931B2 (https=)
CA (1) CA2720616C (https=)
DK (1) DK2274005T3 (https=)
ES (1) ES2425308T3 (https=)
NZ (1) NZ588435A (https=)
PL (1) PL2274005T3 (https=)
PT (1) PT2274005E (https=)
WO (1) WO2009124330A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
WO2013182237A1 (en) * 2012-06-06 2013-12-12 Apeiron Biologics Ag Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
KR20150110607A (ko) * 2013-01-14 2015-10-02 아페이론 바이오로직스 아게 변형된 ａｃｅ２ 폴리펩티드
EP3079684B1 (en) * 2013-12-11 2019-11-13 Alterras Therapeutics GmbH Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2018204385A1 (en) * 2017-05-02 2018-11-08 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
US11337909B2 (en) 2017-11-29 2022-05-24 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
US20250009853A1 (en) 2021-12-03 2025-01-09 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
DE60324925D1 (de) * 2002-06-19 2009-01-08 Univ Health Network Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Also Published As

Publication number Publication date
PT2274005E (pt) 2013-08-27
WO2009124330A3 (de) 2009-12-10
WO2009124330A2 (de) 2009-10-15
ES2425308T3 (es) 2013-10-14
CA2720616A1 (en) 2009-10-15
NZ588435A (en) 2012-10-26
US20110033524A1 (en) 2011-02-10
JP2011516501A (ja) 2011-05-26
AU2009235931B2 (en) 2015-07-23
PL2274005T3 (pl) 2013-12-31
AU2009235931A1 (en) 2009-10-15
EP2274005B1 (de) 2013-05-29
US8946162B2 (en) 2015-02-03
EP2274005A2 (de) 2011-01-19
EP2644203A1 (de) 2013-10-02
AT506632A1 (de) 2009-10-15
JP5650639B2 (ja) 2015-01-07
DK2274005T3 (da) 2013-08-19

Similar Documents

Publication Publication Date Title
CA2720616C (en) Treatment of tumours
Dai et al. Modular peptide probe for pre/intra/postoperative therapeutic to reduce recurrence in ovarian cancer
TWI584815B (zh) 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
JP4514455B2 (ja) Ｔｎｐ−４７０ポリマー複合体及びその使用
EP3384028B1 (en) Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
EA028590B1 (ru) Ингибиторы мет для повышения эффективности лучевой терапии
Xu et al. Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity
Xia et al. Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia
CN114585384A (zh) 使用C/EBPα saRNA的组合物和方法
JP2021527651A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
Bertilaccio et al. Vasculature‐targeted tumor necrosis factor‐alpha increases the therapeutic index of doxorubicin against prostate cancer
CA2534197A1 (en) Use of a vegf antagonist in combination with radiation therapy
EP3388446A1 (en) Improved angiogenesis-inhibiting peptide and composition for preventing and treating angiogenesis-related disease comprising same as active ingredient
Du et al. Chemotherapy based on “Domino-effect” combined with immunotherapy amplifying the efficacy of an anti-metastatic treatment
CN110215511B (zh) 微肽asrps在治疗癌症中的应用
Guo et al. Pre-clinical efficacy and safety pharmacology of PEGylated recombinant human endostatin
US20240075093A1 (en) Compositions and methods of treating a pi3k mediated disease
Li et al. An albumin-prodrug injectable formulation for synergistic cancer immunotherapy
KR20180109540A (ko) 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도
US20240247031A1 (en) Composition for treating cancer containing telomerase-targeting gnrh antagonist-derived peptide hs1002
US20250025484A1 (en) Polymersome nanoparticles exhausting intracelluar amino acid for cancer therapy and methods thereof
Qiu et al. In situ genetically engineering nanosystem for reversing immunosuppression of cancer-associated fibroblasts in breast cancer radiotherapy
US20080096793A1 (en) Class III Slrp for the Treatment of Cancer
WO2023007360A1 (en) Molecules as anticancer agents for targeted treatment of breast and prostate cancer
JP2021031389A (ja) 放射線治療効果増強剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140326

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250326

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250326